DanijuYFaulknerPBrandtK, et al. (2022) Prefrontal cortex and putamen grey matter alterations in cannabis and tobacco users. J Psychopharmacol36: 1315–1323.
2.
de Paula RodriguesBMCoimbraNC (2022) CB1 receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers. J Psychopharmacol36: 1384–1396.
3.
FabrisDCarvalhoMCBrandãoML, et al. (2022) Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze. J Psychopharmacol36: 1371–1383.
4.
KweeCMvan GervenJMBongaertsFL, et al. (2022) Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool. J Psychopharmacol36: 1299–1314.
5.
LawnWMokryszCLeesR, et al. (2022) The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls. J Psychopharmacol36: 1350–1361.
6.
McCartneyDSuraevASDoohanPT, et al. (2022) Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. J Psychopharmacol36: 1338–1349.
7.
NuttD (2005) Cannabis antagonists: A new era of social psychopharmacology?J Psychopharmacol19: 3–4.
8.
RockKLEnglundAMorleyS, et al. (2022) Can cannabis kill? Characteristics of deaths following cannabis use in England (1998-2020). J Psychopharmacol36: 1362–1370.
9.
WilsonTWSchantellMSpringerS, et al. Regular cannabis use modulates the impact of HIV on the neural dynamics serving cognitive control. J Psychopharmacol36: 1324–1337.
